Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:

Subscribers log in here

Antiviral medications for the treatment of hepatitis B in the HIV-infected patient


The era of highly active antiretroviral therapy (ART) has led to declining rates of opportunistic infections and a new focus on other leading causes of morbidity, such as end-stage liver disease (ESLD) secondary to hepatitis B virus (HBV) infection [1]. The treatment and prevention of hepatitis B has taken on great significance in light of the negative impact HIV has on the natural history of chronic hepatitis B infection.

However, the use of antiviral medications for hepatitis B is complicated by the fact that some of these agents have dual activity against HIV infection. Also the available agents vary widely in efficacy and safety.

This topic will address the clinical data available on the various antiviral agents. Information on the evaluation of the treatment candidate, treatment approach, and patient monitoring, are discussed elsewhere. (See "Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient" and "Treatment of hepatitis B in the HIV-infected patient" and "Evaluation of chronic hepatitis B virus infection in the HIV-infected patient" and "Monitoring the HIV-infected patient with chronic hepatitis B virus infection" and "Immunizations in HIV-infected patients", section on 'Hepatitis B vaccine'.)


Tenofovir has activity against both HIV and HBV. Like adefovir, tenofovir is a nucleotide reverse transcriptase inhibitor with activity against lamivudine-resistant virus [2-4]. The efficacy and safety of tenofovir has been evaluated in small substudies within two phase III clinical trials of tenofovir for the treatment of HIV in antiretroviral-naive and experienced patients. HIV/HBV coinfected patients treated with tenofovir experienced significant HBV viral load declines compared to placebo [2]. Tenofovir was also effective against lamivudine resistant virus [4-6]. Development of resistance to tenofovir has not been demonstrated in HIV/HBV coinfection, but the duration of treatment in these small trials was only 24 weeks.

These data prompted a randomized, double-blind placebo-controlled trial of adefovir compared to tenofovir in 52 HIV/HBV co-infected patients on stable HAART [7]. At baseline, median serum HBV DNA levels were 8.7 log(10) copies/microL and 9.3 log(10) copies/microL in the adefovir and tenofovir arms, respectively. After a median duration of follow-up of 75 weeks, mean log HBV DNA declines were -4.4 logs and -3.2 logs on tenofovir and adefovir, respectively.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Aug 2014. | This topic last updated: Feb 18, 2011.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
  1. Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632.
  2. Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189:1185.
  3. Núñez M, Pérez-Olmeda M, Díaz B, et al. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 2002; 16:2352.
  4. Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003; 348:177.
  5. Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals. AIDS 2003; 17:F7.
  6. Ristig MB, Crippin J, Aberg JA, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002; 186:1844.
  7. Peters, M, Anderson, J, Lynch, P, et al. Tenofovir disoproxil fumarate is not inferior to adefovir dipivoxil for the treatment of hepatitis B virus in subjects who are coinfected with HIV: Results of ACTG A5127. Presented at the 11th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February, 2005; abstract #124.
  8. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40:1194.
  9. Dore GJ, Cooper DA, Barrett C, et al. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 1999; 180:607.
  10. Benhamou Y, Katlama C, Lunel F, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996; 125:705.
  11. Hoff J, Bani-Sadr F, Gassin M, Raffi F. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin Infect Dis 2001; 32:963.
  12. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30:1302.
  13. Miailhes P, Trabaud MA, Pradat P, et al. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis 2007; 45:624.
  14. Matthews GV, Bartholomeusz A, Locarnini S, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20:863.
  15. Locarnini S, Warner N. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV. Antivir Ther 2007; 12 Suppl 3:H15.
  16. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000; 31:1318.
  17. Bessesen M, Ives D, Condreay L, et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999; 28:1032.
  18. Altfeld M, Rockstroh JK, Addo M, et al. Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. J Hepatol 1998; 29:306.
  19. McGovern B. What drives hepatitis B virus-related hepatic flares? Virus, T cells--or a bit of both? Clin Infect Dis 2004; 39:133.
  20. Saag MS. Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus. Clin Infect Dis 2006; 42:126.
  21. Snow, A, Harris, J, Borroto-Esoda, K, et al. Emtricitabine therapy for hepatitis infection in HIV+ patients co-infected with hepatitis B virus: efficacy and genotypic findings in antiretroviral treatment-naive patients. Presented at the 11th Conference on Retroviruses and Opportunistic Infections, Boston, MA Abstract #836.
  22. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358:718.
  23. Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006; 44:62.
  24. Delaugerre C, Marcelin AG, Thibault V, et al. Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob Agents Chemother 2002; 46:1586.
  25. McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med 2007; 356:2614.
  26. Audsley, J, Sasadeusa, J, Mijch, A, et al. The anti-HIV activity of entecavir: serum HIV RNA decreases and selection of the M184V mutation occurs in both ART-naive and experienced HIV/HBV coinfected patients. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February, 3-6, 2008; abstract #63.
  27. Pessoa, W, Gazzard, B, Huang, A, et al. Entecavir in HIV/HBV co-infected patients: safety and efficacy in a phase II study (ETV-038). Presented at the 11th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February, 2005; abstract #123.
  28. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576.
  29. Low, E. Telbivudine has activity against HIV. Presented at the 16th Annual Conference on Retroviruses and Opportunistic Infections, Montreal, Canada February 8-11th, 2009; abstract # 813a.
  30. Piroth L, Sène D, Pol S, et al. Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY). AIDS 2007; 21:1323.
  31. Hoofnagle JH, Peters M, Mullen KD, et al. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95:1318.
  32. Brook MG, McDonald JA, Karayiannis P, et al. Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut 1989; 30:1116.
  33. Brook MG, Chan G, Yap I, et al. Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection. BMJ 1989; 299:652.
  34. Wong DK, Yim C, Naylor CD, et al. Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology 1995; 108:165.
  35. Porchon C, Kremsdorf D, Pol S, et al. Serum hepatitis C virus RNA and hepatitis B virus DNA in non-A, non-B post-transfusional and sporadic chronic hepatitis. J Hepatol 1992; 16:184.
  36. Di Martino V, Thevenot T, Colin JF, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002; 123:1812.
  37. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438.